Meglumine antimoniate

**Indication**
Mucocutaneous leishmaniasis

**ICD11 code:** 1F54.2

**Medicine type**
Chemical agent

**List type**
Core (EML) (EMLc)

**Formulations**
Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule

**EML status history**
- First added in 1987 (TRS 770)
- Changed in 1989 (TRS 796)
- Changed in 2002 (TRS 914)
- Changed in 2007 (TRS 950)
- Changed in 2009 (TRS 958)
- Changed in 2009 (TRS 958)
- Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Wikipedia**
Meglumine antimoniate

**DrugBank**
Meglumine antimoniate (Pentavalent Antimony)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule.